3-iodobenzylguanidine has been researched along with Movement Disorders in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cason, E; Fagioli, G; Gabellini, A; Giordano, A; Treglia, G | 1 |
| Braune, S; Del Tredici, K; Jost, WH; Landvogt, C | 1 |
| Kishi, M; Ogawa, E; Sakakibara, R; Tateno, F | 1 |
| Becker, G; Benecke, R; Braune, S; Büttner, T; Greulich, W; Klein, W; Mark, G; Müller, A; Rieke, J; Thümler, R | 1 |
| Kim, JS; Lee, KS; Song, IU | 1 |
| Annesi, F; Annesi, G; Bagnato, A; Candiano, IC; Civitelli, D; Condino, F; D'Amelio, M; Loizzo, P; Morelli, M; Morgante, L; Nicoletti, G; Novellino, F; Petrone, A; Quattrone, A; Rocca, FE; Savettieri, G; Tarantino, P; Zappia, M | 1 |
2 review(s) available for 3-iodobenzylguanidine and Movement Disorders
| Article | Year |
|---|---|
Recent developments in innervation imaging using iodine-123-metaiodobenzylguanidine scintigraphy in Lewy body diseases.
Topics: 3-Iodobenzylguanidine; Diagnosis, Differential; Extrapyramidal Tracts; Heart; Humans; Lewy Bodies; Movement Disorders; Myocardium; Parkinson Disease; Radionuclide Imaging; Radiopharmaceuticals | 2010 |
Early diagnosis of Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Affect; Biomarkers; Handwriting; Heart; Humans; Iron; Mood Disorders; Movement Disorders; Mutation; Olfaction Disorders; Parkinson Disease; Peripheral Nervous System Diseases; Psychomotor Performance; Radiopharmaceuticals; Risk Assessment; Risk Factors; Speech; Substantia Nigra; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Ultrasonography; Vision, Ocular | 2002 |
4 other study(ies) available for 3-iodobenzylguanidine and Movement Disorders
| Article | Year |
|---|---|
Importance of 123I-metaiodobenzylguanidine scintigraphy/single photon emission computed tomography for diagnosis and differential diagnostics of Parkinson syndromes.
Topics: 3-Iodobenzylguanidine; Antithyroid Agents; Brain; Diagnosis, Differential; Early Diagnosis; False Negative Reactions; False Positive Reactions; Humans; Image Interpretation, Computer-Assisted; Movement Disorders; Parkinson Disease; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2010 |
Pure akinesia with low myocardial metaiodobenzylguanidine uptake.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Female; Heart; Humans; Male; Mental Status Schedule; Movement Disorders; Tomography, Emission-Computed, Single-Photon | 2011 |
Dopa-responsive camptocormia in a patient with multiple system atrophy.
Topics: 3-Iodobenzylguanidine; Antiparkinson Agents; Female; Heart; Humans; Levodopa; Middle Aged; Movement; Movement Disorders; Multiple System Atrophy; Parkinson Disease; Posture; Radionuclide Imaging; Radiopharmaceuticals | 2008 |
Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Adult; Diagnosis, Differential; DNA Mutational Analysis; Female; Galvanic Skin Response; Genotype; Humans; Intracellular Signaling Peptides and Proteins; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Middle Aged; Movement Disorders; Myocardium; Oncogene Proteins; Parkinson Disease; Parkinsonian Disorders; Point Mutation; Promoter Regions, Genetic; Protein Deglycase DJ-1; Protein Kinases; Protein Serine-Threonine Kinases; Radiopharmaceuticals; Severity of Illness Index; Surveys and Questionnaires; Tomography, Emission-Computed, Single-Photon; Ubiquitin-Protein Ligases | 2008 |